Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.

M. Davidson*, L. M. Bierer, R. Kaminsky, T. M. Ryan, K. L. Davis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Reports of cholinergic and noradrenergic deficits in brain specimens from Alzheimer patients have suggested that concomitant augmentation of cholinergic and noradrenergic neurotransmission can benefit some dementia of the Alzheimer type (DAT) patients. However, pharmacological agents that enhance central cholinergic and noradrenergic neurotransmission, like physostigmine and clonidine, might have serious adverse effects. Therefore, prior to the commitment of major resources in efficacy studies, feasibility pilot studies are necessary to ensure that physostigmine and clonidine, combined, can be safely administered to DAT patients. Physostigmine, 2 mg every 2 h, and clonidine, up to 0.3 mg/day, were tolerated by the nine DAT patients without clinically meaningful adverse effects.

Original languageEnglish
Pages (from-to)224-227
Number of pages4
JournalAlzheimer Disease and Associated Disorders
Volume3
Issue number4
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Dive into the research topics of 'Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.'. Together they form a unique fingerprint.

Cite this